Mylan and Horizon launch their hostile bids
This article was originally published in Scrip
Executive Summary
Horizon Pharma plc.'s hostile bid for Depomed, Inc got out of the blocks on Sep. 8 after weeks of wrangling with Depomed's board. It has now taken an exchange offer direct to the latter's shareholders, which will run until Nov. 6. The offer of 0.95 Horizon shares for each Depomed share equates to a takeover value of $1.7bn based on Horizon's share price of $29.72 on Nasdaq before markets opened on Sep. 9. Ireland-based Horizon continues to push for meetings for Depomed's shareholders to vote on its proposal to replace the current Depomed board with its own slate of directors and to amend bylaws. With stock market fluctuations the latest all-stock offer is now worth less than Horizon's previous offer, which had also included a portion in cash. Depomed, of Newark, California, advised its shareholders to take no action while it reviewed the offer.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.